These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34742252)

  • 21. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
    Garland SG; Smith SM; Gums JG
    Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
    [No Abstract]   [Full Text] [Related]  

  • 22. Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study.
    Gladstone J; Chhibber S; Minhas J; Neish CS; Power GS; Lan Z; Rochdi D; Lanthier-Martel J; Bastien N
    Headache; 2022 Jan; 62(1):78-88. PubMed ID: 34807454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective real-world analysis of erenumab in refractory chronic migraine.
    Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
    J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology].
    Dobrynina LA; Gubanova MV; Belopasova AV; Baydina EV; Afanasev MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(2):74-80. PubMed ID: 35271240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience.
    Mahović D; Bračić M; Jakuš L; Vukovic Cvetkovic V; Krpan M
    Clin Neurol Neurosurg; 2022 Mar; 214():107169. PubMed ID: 35151970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
    J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Controlled Trial of Erenumab for Episodic Migraine.
    Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
    N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
    Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
    J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.
    Guerzoni S; Baraldi C; Pensato U; Favoni V; Lo Castro F; Cainazzo MM; Cevoli S; Pani L
    Neurol Sci; 2022 Jun; 43(6):3823-3830. PubMed ID: 35015202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.
    Ornello R; Casalena A; Frattale I; Gabriele A; Affaitati G; Giamberardino MA; Assetta M; Maddestra M; Marzoli F; Viola S; Cerone D; Marini C; Pistoia F; Sacco S
    J Headache Pain; 2020 Apr; 21(1):32. PubMed ID: 32264820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erenumab efficacy in migraine headache prophylaxis: A systematic review.
    Bagherzadeh-Fard M; Amin Yazdanifar M; Sadeghalvad M; Rezaei N
    Int Immunopharmacol; 2023 Apr; 117():109366. PubMed ID: 37012858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.
    Troy E; Shrukalla AA; Buture A; Conaty K; Macken E; Lonergan R; Melling J; Long N; Shaikh E; Birrane K; Tomkins EM; Goadsby PJ; Ruttledge MH
    J Headache Pain; 2023 Jan; 24(1):5. PubMed ID: 36647006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timing and durability of response to erenumab in patients with episodic migraine.
    McAllister PJ; Turner I; Reuter U; Wang A; Scanlon J; Klatt J; Chou DE; Paiva da Silva Lima G
    Headache; 2021 Nov; 61(10):1553-1561. PubMed ID: 34841526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study.
    Lanteri-Minet M; Fabre R; Martin C; Pradat K; Alchaar A; Bozzolo E; Duchene ML; Van Obberghen EK; Donnet A; Fontaine D
    J Headache Pain; 2023 Nov; 24(1):152. PubMed ID: 37940860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world experiences of migraine patients on Erenumab: a Kuwait single center cohort.
    Al-Hashel JY; Alroughani R; Alshaf F; Ashkanani HK; Akl A; AlMutairi O; Alwazzan S; Ahmed SF
    Neurol Res; 2024 Aug; 46(8):772-780. PubMed ID: 38909320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study.
    Tepper SJ; Fang J; Vo P; Shen Y; Zhou L; Abdrabboh A; Glassberg M; Ferraris M
    J Headache Pain; 2021 Apr; 22(1):27. PubMed ID: 33874884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region.
    Ornello R; Casalena A; Frattale I; Caponnetto V; Gabriele A; Affaitati G; Giamberardino MA; Assetta M; Maddestra M; Marzoli F; Viola S; Cerone D; Marini C; Pistoia F; Sacco S
    J Headache Pain; 2020 Aug; 21(1):102. PubMed ID: 32799790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study.
    de Vries Lentsch S; Verhagen IE; van den Hoek TC; MaassenVanDenBrink A; Terwindt GM
    Eur J Neurol; 2021 Dec; 28(12):4194-4203. PubMed ID: 34424593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
    Cullum CK; Do TP; Ashina M; Bendtsen L; Hugger SS; Iljazi A; Gusatovic J; Snellman J; Lopez-Lopez C; Ashina H; Amin FM
    J Headache Pain; 2022 Jun; 23(1):61. PubMed ID: 35655137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
    Buse DC; Lipton RB; Hallström Y; Reuter U; Tepper SJ; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
    Cephalalgia; 2018 Sep; 38(10):1622-1631. PubMed ID: 30086681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.